Deep Lens today announced a collaboration that will integrate Deep Lens’ artificial intelligence (AI)-based clinical trial screening and matching solution VIPER™ , into cancer research. VIPER uses proprietary cloud-based technology to facilitate, triage and accelerate the clinical trial recruitment process. The technology will be used at Norton Cancer Institute, the largest provider of cancer care in the Louisville, Ky., area. VIPER will be used to streamline the patient recruitment process by minimizing resource constraints and enabling immediate access to a greater number of clinical trials.
It is estimated that more than 15,000 oncology clinical trials are actively recruiting patients; however, patient participation in these trials is often as low as three percent. The challenges associated with accrual to cancer-focused research studies are complex and have been magnified by the current global pandemic. VIPER automates the clinical trial screening process and seamlessly matches patients — at the time of diagnosis — to appropriate trials through the ingestion and analysis of customized genomic, electronic medical record and pathology data.
“Deep Lens is committed to making it easier for cancer patients to find trials that may optimize their care and potentially impact the course of their disease,” said Greg Andreola, chief revenue officer for Deep Lens. “We are confident that VIPER will help reinforce Norton Cancer Institute’s prominent reputation in Kentucky and Southern Indiana and we look forward to bringing more opportunities for patients to receive access to cutting-edge therapies in development.”
Deep Lens’ VIPER integrates directly into electronic medical records such as Epic, molecular data feeds (Caris, Foundation, and in-house labs) and pathology feeds to automatically identify qualified patients for clinical trials. Any practice that utilizes Epic can easily integrate VIPER and all other Deep Lens screening services free of charge.